US patent reforms could re-establish gene patent eligibility, industry experts warn
A group of more than 100 medical, scientific, patient advocacy and women’s health organisations have opposed a recent proposal to amend section 101 of the US Patent Act.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 March 2019 The Information Technology and Innovation Foundation think tank has called on the US National Institutions of Health to maintain IP protection amid calls to “break” patents in order to lower drug prices.
5 March 2019 The Information Technology and Innovation Foundation think tank has called on the US National Institutions of Health to maintain IP protection amid calls to “break” patents in order to lower drug prices.
5 March 2019 The Information Technology and Innovation Foundation think tank has called on the US National Institutions of Health to maintain IP protection amid calls to “break” patents in order to lower drug prices.